Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

793 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Circulating Cystatin C Is an Independent Risk Marker for Cardiovascular Outcomes, Development of Renal Impairment, and Long-Term Mortality in Patients With Stable Coronary Heart Disease: The LIPID Study.
West M, Kirby A, Stewart RA, Blankenberg S, Sullivan D, White HD, Hunt D, Marschner I, Janus E, Kritharides L, Watts GF, Simes J, Tonkin AM; LIPID Study Group *. West M, et al. Among authors: blankenberg s. J Am Heart Assoc. 2022 Mar;11(5):e020745. doi: 10.1161/JAHA.121.020745. Epub 2022 Feb 18. J Am Heart Assoc. 2022. PMID: 35179040 Free PMC article.
The value of N-terminal fragment of brain natriuretic peptide and tissue inhibitor of metalloproteinase-1 levels as predictors of cardiovascular outcome in the LIPID study.
West MJ, Nestel PJ, Kirby AC, Schnabel R, Sullivan D, Simes RJ, Pollicino C, Lubos E, Münzel TF, White HD, Tonkin AM, Bickel C, Tiret L, Blankenberg S; LIPID Study Investigators. West MJ, et al. Among authors: blankenberg s. Eur Heart J. 2008 Apr;29(7):923-31. doi: 10.1093/eurheartj/ehn007. Epub 2008 Feb 22. Eur Heart J. 2008. PMID: 18296678
Cystatin C and cardiovascular mortality in patients with coronary artery disease and normal or mildly reduced kidney function: results from the AtheroGene study.
Keller T, Messow CM, Lubos E, Nicaud V, Wild PS, Rupprecht HJ, Bickel C, Tzikas S, Peetz D, Lackner KJ, Tiret L, Münzel TF, Blankenberg S, Schnabel RB. Keller T, et al. Among authors: blankenberg s. Eur Heart J. 2009 Feb;30(3):314-20. doi: 10.1093/eurheartj/ehn598. Epub 2009 Jan 19. Eur Heart J. 2009. PMID: 19153178
Multiple marker approach to risk stratification in patients with stable coronary artery disease.
Schnabel RB, Schulz A, Messow CM, Lubos E, Wild PS, Zeller T, Sinning CR, Rupprecht HJ, Bickel C, Peetz D, Cambien F, Kempf T, Wollert KC, Benjamin EJ, Lackner KJ, Münzel TF, Tiret L, Vasan RS, Blankenberg S. Schnabel RB, et al. Among authors: blankenberg s. Eur Heart J. 2010 Dec;31(24):3024-31. doi: 10.1093/eurheartj/ehq322. Epub 2010 Sep 18. Eur Heart J. 2010. PMID: 20852293
Plasma lipoprotein(a) concentration predicts future coronary and cardiovascular events in patients with stable coronary heart disease.
Nestel PJ, Barnes EH, Tonkin AM, Simes J, Fournier M, White HD, Colquhoun DM, Blankenberg S, Sullivan DR. Nestel PJ, et al. Among authors: blankenberg s. Arterioscler Thromb Vasc Biol. 2013 Dec;33(12):2902-8. doi: 10.1161/ATVBAHA.113.302479. Epub 2013 Oct 3. Arterioscler Thromb Vasc Biol. 2013. PMID: 24092750 Clinical Trial.
High population prevalence of cardiac troponin I measured by a high-sensitivity assay and cardiovascular risk estimation: the MORGAM Biomarker Project Scottish Cohort.
Zeller T, Tunstall-Pedoe H, Saarela O, Ojeda F, Schnabel RB, Tuovinen T, Woodward M, Struthers A, Hughes M, Kee F, Salomaa V, Kuulasmaa K, Blankenberg S; MORGAM Investigators. Zeller T, et al. Among authors: blankenberg s. Eur Heart J. 2014 Feb;35(5):271-81. doi: 10.1093/eurheartj/eht406. Epub 2013 Oct 8. Eur Heart J. 2014. PMID: 24104876
Association of contemporary sensitive troponin I levels at baseline and change at 1 year with long-term coronary events following myocardial infarction or unstable angina: results from the LIPID Study (Long-Term Intervention With Pravastatin in Ischaemic Disease).
White HD, Tonkin A, Simes J, Stewart R, Mann K, Thompson P, Colquhoun D, West M, Nestel P, Sullivan D, Keech AC, Hunt D, Blankenberg S; LIPID Study Investigators. White HD, et al. Among authors: blankenberg s. J Am Coll Cardiol. 2014 Feb 4;63(4):345-54. doi: 10.1016/j.jacc.2013.08.1643. Epub 2013 Oct 30. J Am Coll Cardiol. 2014. PMID: 24140630 Free article. Clinical Trial.
Changes in lipoprotein-Associated phospholipase A2 activity predict coronary events and partly account for the treatment effect of pravastatin: results from the Long-Term Intervention with Pravastatin in Ischemic Disease study.
White HD, Simes J, Stewart RA, Blankenberg S, Barnes EH, Marschner IC, Thompson P, West M, Zeller T, Colquhoun DM, Nestel P, Keech AC, Sullivan DR, Hunt D, Tonkin A; LIPID Study Investigators. White HD, et al. Among authors: blankenberg s. J Am Heart Assoc. 2013 Oct 23;2(5):e000360. doi: 10.1161/JAHA.113.000360. J Am Heart Assoc. 2013. PMID: 24152981 Free PMC article. Clinical Trial.
Midregional proadrenomedullin and its change predicts recurrent major coronary events and heart failure in stable coronary heart disease patients: the LIPID study.
Funke-Kaiser A, Mann K, Colquhoun D, Zeller T, Hunt D, Simes J, Sullivan D, Sydow K, West M, White H, Blankenberg S, Tonkin AM; LIPID Study Investigators. Funke-Kaiser A, et al. Among authors: blankenberg s. Int J Cardiol. 2014 Mar 15;172(2):411-8. doi: 10.1016/j.ijcard.2014.01.064. Epub 2014 Jan 24. Int J Cardiol. 2014. PMID: 24508492 Clinical Trial.
793 results